Granted Patent B2

US 12,485,169 · App. 17/295,335 · Granted Dec 2, 2025

Inventors: Martin Quibell (Oxford, GB); Anil Lallubhai Patel (Oxford, GB); Jason John Shiers (Oxford, GB); Michael Sparenberg (Oxford, GB); Peter Ian Joyce (Oxford, GB)

Assignee: Grey Wolf Therapeutics Limited

A61K39/39A61K31/397A61K31/402A61K31/4035A61K31/407A61K31/41A61K31/438A61K31/439A61K31/451A61K31/454A61K31/495A61K31/497A61K31/4985A61K31/501A61K31/55A61K31/553A61K35/17A61K39/00A61K39/3955C07D205/04C07D207/12C07D209/44C07D211/14C07D211/38C07D211/44C07D211/48C07D295/135C07D471/08C07D487/04C07D491/107C07D498/08A61K2039/5154C07B2200/05

Abstract

Claims (79)

1 . A compound of formula (Id), or a pharmaceutically acceptable salt or hydrate thereof,

wherein:

the group X—Y is —NHSO 2 — or —SO 2 NH—;

R 1 is H or alkyl;

R 2 is selected from COOH and a tetrazolyl group;

R 3 is selected from H, Cl and alkyl;

R 4 is selected from H, Cl and F;

R 5 is selected from alkyl, alkenyl, alkynyl, haloalkyl, SO 2 -alkyl, Cl, alkoxy, OH, CN, hydroxyalkyl, alkylthio, heteroaryl, cycloalkyl, heterocycloalkyl and haloalkoxy;

R 6 is H;

R 7 is CN, SO 2 -alkyl, SO 2 NR 13 R 14 or a heteroaryl group, wherein said heteroaryl group is optionally substituted by one or more substituents selected from alkyl, halo, alkoxy, CN, haloalkyl and OH;

R 8 is selected from H, alkyl, haloalkyl and halo;

R 9 is H, C 1 -C 3 -alkyl or halo;

R 10 and R 11 , together with the nitrogen to which they are attached, form a 4, 5, 6 or 7-membered monocyclic heterocycloalkyl group, wherein one or two carbons in the monocyclic heterocycloalkyl group are optionally replaced by a group selected from O, NH, S and CO, and said monocyclic heterocycloalkyl group is optionally substituted by one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl and heteroaryl, wherein said heteroaryl group is in turn optionally further substituted with one or more groups selected from halo and alkyl; or

R 10 and R 11 , together with the nitrogen to which they are attached, form an 8, 9 or 10-membered bicyclic heterocycloalkyl group, wherein one or two carbons in the bicyclic heterocycloalkyl ring are optionally replaced by a group selected from O, NH, S and CO, and said bicyclic heterocycloalkyl group is optionally substituted by one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl and heteroaryl; or

R 10 and R 11 , together with the nitrogen to which they are attached, form a 6 to 12-membered bicyclic group containing a spirocyclic carbon atom, wherein one or two carbons in the bicyclic group are optionally replaced by a group selected from O, NH, S and CO, and said bicyclic group is optionally substituted by one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl and heteroaryl, or said bicyclic group is optionally fused to a 5 or 6-membered aryl or heteroaryl group; and

R 13 and R 14 are each H.

2 . The compound according to claim 1 , wherein R 10 and R 11 , together with the nitrogen to which they are attached, form a 6-membered monocyclic heterocycloalkyl group, wherein one or two carbons in the monocyclic heterocycloalkyl group are optionally replaced by a group selected from O, NH, S and CO, and said monocyclic heterocycloalkyl group is optionally substituted by one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl and heteroaryl, wherein said heteroaryl group is in turn optionally further substituted with one or more groups selected from halo and alkyl.

3 . The compound of claim 1 , wherein R 10 and R 11 , together with the nitrogen to which they are attached, form a piperidinyl group which is optionally substituted by one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl, and heteroaryl, wherein said heteroaryl group is in turn optionally further substituted with one or more groups selected from halo and alkyl.

4 . The compound of claim 1 , wherein R 10 and R 11 , together with the nitrogen to which they are attached, form an unsubstituted piperidinyl group.

5 . The compound according to claim 1 , wherein R 7 is a heteroaryl group selected from imidazolyl, pyrazolyl, pyrazinyl, pyradizinyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, tetrazolyl and triazolyl, each of which is optionally substituted by one or more substituents selected from alkyl, halo, alkoxy, CN, haloalkyl and OH.

6 . The compound of claim 1 , wherein R 7 is CN.

7 . The compound of claim 1 , wherein R 8 is selected from H, Me, CF 3 , Cl, Br, and F.

8 . The compound of claim 1 , wherein R 2 is COOH.

9 . The compound according to claim 1 , wherein the compound of formula (Id) is selected from the following:

(182)

(207)

(214)

(215)

(241)

(242)

(259)

(261)

(273)

(274)

(275)

(276)

(277)

(278)

(279)

(280)

(281)

(282)

(286)

(287)

(288)

(289)

(290)

(291)

(292)

(293)

(295)

(296)

(297)

(298)

(299)

(300)

(301)

(302)

(303)

(304)

(305)

(306)

(323)

(324)

(327)

(329)

(330)

(331)

(332)

(333)

(334)

(335)

(336)

(337)

(338)

and pharmaceutically acceptable salts and hydrates thereof.

10 . The compound of claim 1 , having the following structure:

or a pharmaceutically acceptable salt or hydrate thereof.

11 . A pharmaceutical composition comprising a compound according to claim 1 admixed with a pharmaceutically acceptable diluent, excipient or carrier.

Assignments (1)

Priority Claims (4)

Continuity (1)

References Cited (113)